Business Analyst, Ceribell

Though founded back in 2014, Ceribell experienced a huge breakthrough in 2022 when its system was granted FDA clearance to help diagnose suspected seizures, which has led to a boost in venture capital investment.

The company has also gone on to receive the FDA’s Breakthrough Device Designation for its ability to diagnose delirium, or acute brain failure. It was featured on Fast Company's World's Most Innovative Companies List 2023. Ceribell has no plans on stopping there, though, and intends to grow its team rapidly in a bid to expand its tech capabilities for a range of other neurological conditions.